VKTX
Viking Therapeutics, Inc.
Set alert
- YTD
- -22.46%
- 1 year
- -28.53%
- Open
- 26.69
- Prev close
- 26.86
- Mkt cap
- 3.48B
- Vol
- 5.14M
- Avg vol
- 4.74M
- EPS
- -5.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.31
- High
- 27.83
- Forward P/E
- -5.39
- Beta
- 0.65
- Short ratio
- 2.88
- Inst. own
- 60.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 10, 2027
- 50-d avg
- 30.65
- 200-d avg
- 32.44
- 1y target
- 95.32
Key statistics
- Market cap
- 3.48B
- Enterprise value
- 2.72B
- Trailing P/E
- 0.00
- Forward P/E
- -5.39
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.91
- EPS (TTM)
- -5.42
- Beta
- 0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 959.81M
- Total debt
- 254.69M
- Return on equity
- -96.37%
- Shares outstanding
- 127.52M
- Short % of float
- 21.06%
- 50-day average
- 30.65
- 200-day average
- 32.44
Analyst view
Consensus: strong buy
- Target (low)
- 34.00
- Target (mean)
- 95.32
- Target (high)
- 125.00
- Strong buy5
- Buy14
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate -1.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | -1.36 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | -1.06 | -1.55 | -0.49 | -46.23% |
| Jul 29, 2026 | Jun 30, 2026 | -1.23 | -1.10 | +0.13 | +10.57% |
| Apr 29, 2026 | Mar 31, 2026 | -1.01 | -1.37 | -0.36 | -35.64% |
| Feb 11, 2026 | Dec 31, 2025 | -0.89 | -1.38 | -0.49 | -55.06% |
| Oct 22, 2025 | Sep 30, 2025 | -0.70 | -0.81 | -0.11 | -15.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 15, 2026 | UBS | init | — | Buy |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 23, 2026 | Truist Securities | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 30, 2026 | Canaccord Genuity | main | Buy | Buy |
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vikingtherapeutics.com
News
- Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118
- VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
- Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
- Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
- VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
- Viking Therapeutics Stock Jumps: What's Going On?
- Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
- Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock
- Viking Therapeutics Q3 Earnings Call Highlights
Your note
Sign in to keep a note on VKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUBUCHON NEIL WILLIAM | Officer | Purchase | Mar 9, 2026 | 4,475 |
| FOEHR MATTHEW W | Director | Stock Award(Grant) | Jan 1, 2026 | 135,186 |
| KELLY-GEMMELL DOROTHY ELIZABETH | Director | Stock Award(Grant) | Jul 30, 2026 | 6,333 |
| LIAN BRIAN | Chief Executive Officer | Sale | Jul 28, 2026 | 2,572,440 |
| MACARTNEY LAWSON | Director | Stock Award(Grant) | Jan 1, 2026 | 51,115 |
| MANCINI MARIANNA | Chief Operating Officer | Sale | Jul 28, 2026 | 422,760 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 5.03% | 6,335,756 | 172.84M | Jun 29, 2026 |
| Blackrock Inc. | 4.91% | 6,189,649 | 168.85M | Jun 29, 2026 |
| State Street Corporation | 4.45% | 5,606,394 | 152.94M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.01% | 5,053,663 | 137.86M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.56% | 4,484,263 | 122.33M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.13% | 3,937,414 | 107.41M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.78% | 3,500,175 | 95.48M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.73% | 3,444,940 | 93.98M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.01% | 2,528,235 | 68.97M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.16% | 1,458,461 | 39.79M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06% | 1,333,178 | 36.37M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-HERITAGE FUND | 1.06% | 1,331,574 | 36.33M | Jul 30, 2026 |